Q-omics provides the consensus-scored PCDHA12 profile across patient tissues and cancer cell-line models. PCDHA12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PCDHA12 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PCDHA12 RNA expression shows 14,095 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight LUSC, KIRC, and PCPG as cancer lineages where PCDHA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHA12 survival associations across molecular data types. PCDHA12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHA12 RNA expression–survival associations across cancer types. High PCDHA12 expression shows unfavorable associations in LUSC, STAD, CHOL and LUAD, but favorable associations in KIRC and UVM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PCDHA12 RNA expression.
This table summarizes PCDHA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHA12 shows lower tumor expression in KIRC, LUSC, LUAD, KICH and THCA and higher tumor expression in BRCA. The KIRC box plot shows higher PCDHA12 RNA expression in normal versus tumor tissue (log2 FC = −1.019, t-test p < 0.001).
This table shows molecular features associated with PCDHA12 in patient tissues and cancer cell lines. In patient samples, PCDHA12 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
